These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9591937)

  • 1. Rifaximin systemic absorption in patients with ulcerative colitis.
    Rizzello F; Gionchetti P; Venturi A; Ferretti M; Peruzzo S; Raspanti X; Picard M; Canova N; Palazzini E; Campieri M
    Eur J Clin Pharmacol; 1998 Mar; 54(1):91-3. PubMed ID: 9591937
    [No Abstract]   [Full Text] [Related]  

  • 2. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.
    Gionchetti P; Rizzello F; Ferrieri A; Venturi A; Brignola C; Ferretti M; Peruzzo S; Miglioli M; Campieri M
    Dig Dis Sci; 1999 Jun; 44(6):1220-1. PubMed ID: 10389700
    [No Abstract]   [Full Text] [Related]  

  • 3. Rifaximin for active ulcerative colitis.
    Guslandi M; Petrone MC; Testoni PA
    Inflamm Bowel Dis; 2006 Apr; 12(4):335. PubMed ID: 16633057
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of inflammatory bowel disease: does rifaximin offer any promise?
    Gionchetti P; Rizzello F; Morselli C; Romagnoli R; Campieri M
    Chemotherapy; 2005; 51 Suppl 1():96-102. PubMed ID: 15855753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin for inflammatory bowel disease.
    Guslandi M
    Dig Dis Sci; 2010 Jun; 55(6):1805. PubMed ID: 20428944
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical-therapeutic considerations in the treatment of aspecific abdominal disturbances in patients with ulcerative colitis in remission: preliminary note on therapy with rifaximin].
    Riegler G; Russo MI; Carratù R; Ferrieri A
    Riv Eur Sci Med Farmacol; 1992 Feb; 14(1):9-14. PubMed ID: 1529151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.
    Brigidi P; Swennen E; Rizzello F; Bozzolasco M; Matteuzzi D
    J Chemother; 2002 Jun; 14(3):290-5. PubMed ID: 12120885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach.
    Gionchetti P; Rizzello F; Venturi A; Ugolini F; Rossi M; Brigidi P; Johansson R; Ferrieri A; Poggioli G; Campieri M
    Eur Rev Med Pharmacol Sci; 1999; 3(1):27-30. PubMed ID: 10710827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis.
    Guslandi M
    J Clin Gastroenterol; 2010; 44(5):385. PubMed ID: 20104184
    [No Abstract]   [Full Text] [Related]  

  • 10. Use and safety of rifaximin in children with inflammatory bowel disease.
    Muniyappa P; Gulati R; Mohr F; Hupertz V
    J Pediatr Gastroenterol Nutr; 2009 Oct; 49(4):400-4. PubMed ID: 19668011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
    Sartor RB
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers.
    Blandizzi C; Viscomi GC; Marzo A; Scarpignato C
    Pharmacol Res; 2014 Jul; 85():39-44. PubMed ID: 24836868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimycobacterial activity of rifaximin (L/105) in experimental tuberculosis in the guinea pig.
    Lucchesi M; Marchi E; Venturini AP
    Chemioterapia; 1984 Dec; 3(6):371-2. PubMed ID: 6442216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic absorption from hydrocortisone foam enema in ulcerative colitis.
    Cann PA; Holdsworth CD
    Lancet; 1987 Apr; 1(8538):922-3. PubMed ID: 2882324
    [No Abstract]   [Full Text] [Related]  

  • 15. Absorption studies in patients with Crohn's disease and in patients with ulcerative colitis.
    Andersson H; Dotevall G; Gillberg G; Jagenburg R; Kock NG
    Acta Med Scand; 1971 Nov; 190(5):407-10. PubMed ID: 5149268
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.
    Descombe JJ; Dubourg D; Picard M; Palazzini E
    Int J Clin Pharmacol Res; 1994; 14(2):51-6. PubMed ID: 7836025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological disposition of a series of rifamycins in rat: a comparative study.
    Assandri A; Cristina T; Moro L
    J Antibiot (Tokyo); 1978 Sep; 31(9):894-901. PubMed ID: 711631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcutaneous absorption of a topical rifamycin preparation: rifaximin (L/105).
    Venturini AP; Bertoli D; Marchi E
    Drugs Exp Clin Res; 1987; 13(4):231-2. PubMed ID: 3622252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
    Singh S; Stroud AM; Holubar SD; Sandborn WJ; Pardi DS
    Cochrane Database Syst Rev; 2015 Nov; (11):CD001176. PubMed ID: 26593456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin in the treatment of recurrent Clostridium difficile infection.
    Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ
    Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.